Literature DB >> 19808057

HIV reservoirs, latency, and reactivation: prospects for eradication.

Viktor Dahl1, Lina Josefsson, Sarah Palmer.   

Abstract

Current antiretroviral therapy effectively suppresses but does not eradicate HIV-1 infection. During therapy patients maintain a persistent low-level viremia requiring lifelong adherence to antiretroviral therapies. This viremia may arise from latently infected reservoirs such as resting memory CD4+ T-cells or sanctuary sites where drug penetration is suboptimal. Understanding the mechanisms of HIV latency will help efforts to eradicate the infection. This review examines the dynamics of persistent viremia, viral reservoirs, the mechanisms behind viral latency, and methods to purge the viral reservoirs. This article forms part of a special issue of Antiviral Research marking the 25th anniversary of antiretroviral drug discovery and development, vol. 85, issue 1, 2010. Copyright 2009 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2009        PMID: 19808057     DOI: 10.1016/j.antiviral.2009.09.016

Source DB:  PubMed          Journal:  Antiviral Res        ISSN: 0166-3542            Impact factor:   5.970


  53 in total

1.  Scaffold rearrangement of dihydroxypyrimidine inhibitors of HIV integrase: Docking model revisited.

Authors:  Jing Tang; Kasthuraiah Maddali; Yves Pommier; Yuk Y Sham; Zhengqiang Wang
Journal:  Bioorg Med Chem Lett       Date:  2010-04-21       Impact factor: 2.823

Review 2.  HIV reservoirs and latency models.

Authors:  Matthew J Pace; Luis Agosto; Erin H Graf; Una O'Doherty
Journal:  Virology       Date:  2011-02-01       Impact factor: 3.616

Review 3.  HIV-1 transcription and latency: an update.

Authors:  Carine Van Lint; Sophie Bouchat; Alessandro Marcello
Journal:  Retrovirology       Date:  2013-06-26       Impact factor: 4.602

Review 4.  New insights into HIV assembly and trafficking.

Authors:  Muthukumar Balasubramaniam; Eric O Freed
Journal:  Physiology (Bethesda)       Date:  2011-08

5.  Plasmacytoid dendritic cell and functional HIV Gag p55-specific T cells before treatment interruption can inform set-point plasma HIV viral load after treatment interruption in chronically suppressed HIV-1(+) patients.

Authors:  Emmanouil Papasavvas; Andrea Foulkes; Xiangfan Yin; Jocelin Joseph; Brian Ross; Livio Azzoni; Jay R Kostman; Karam Mounzer; Jane Shull; Luis J Montaner
Journal:  Immunology       Date:  2015-05-19       Impact factor: 7.397

Review 6.  The development of antiretroviral therapy and its impact on the HIV-1/AIDS pandemic.

Authors:  Samuel Broder
Journal:  Antiviral Res       Date:  2009-12-16       Impact factor: 5.970

7.  HIV infection: what should be considered in approaches for a cure?

Authors:  Jay A Levy; Yves Levy
Journal:  AIDS       Date:  2012-11-13       Impact factor: 4.177

Review 8.  Molecular control of HIV-1 postintegration latency: implications for the development of new therapeutic strategies.

Authors:  Laurence Colin; Carine Van Lint
Journal:  Retrovirology       Date:  2009-12-04       Impact factor: 4.602

9.  Cell line-dependent variability in HIV activation employing DNMT inhibitors.

Authors:  Guerau Fernandez; Steven L Zeichner
Journal:  Virol J       Date:  2010-10-13       Impact factor: 4.099

10.  Profound depletion of HIV-1 transcription in patients initiating antiretroviral therapy during acute infection.

Authors:  Adrian Schmid; Sara Gianella; Viktor von Wyl; Karin J Metzner; Alexandra U Scherrer; Barbara Niederöst; Claudia F Althaus; Philip Rieder; Christina Grube; Beda Joos; Rainer Weber; Marek Fischer; Huldrych F Günthard
Journal:  PLoS One       Date:  2010-10-12       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.